Healthcare Sep 15, 2021 09:15 AM (GMT+8)
Yiouda health learned on the 15th that recently, Shanghai Huihe Medical Technology Co., Ltd. (hereinafter referred to as "Huihe medical") announced the completion of the B + round of financing with an estimated value of nearly 5 billion yuan, which was invested exclusively by Sherpa, a well-known investment fund in the medical field.
Huihe medical has entered the field of structural heart disease since 2018, the first product k-clip ™ (transcatheter tricuspid annulus repair system) has completed its first humanitarian clinical trial and entered the stage of confirmatory multicenter clinical trial. In the process of continuously consolidating R & D capacity, a whole industry platform for cardiac and vascular interventional devices from R & D to clinical, from small-scale test to mass production has been constructed.
On this platform, Huihe medical incorporated vascular intervention products, electrophysiological intervention products and intelligent intervention products into the product pipeline through incubation, merger and strategic joint development. Among them, C-wave is the first product of Zhonghui medical, a subsidiary of Huihe medical ™ (vascular calcification shock wave catheter system) will enter a confirmatory multicenter clinical trial in September. This will also be the second product of Huihe company to enter the confirmatory multicenter clinical trial.
This text is a result of machine translation.